Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Guangdong South China New Drug Creation Center
Guangdong, Chinasccip.org.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
As of early 2025, the center's pipeline includes several clinical-stage small molecule drugs, with two programs in Phase 3. The center is also known for translational medicine efforts and broad collaborations, but specific trial outcomes are not publicly detailed.[4]
- Therapeutic areas
- EndocrinologyInfectious DiseasesPulmonologyCardiovascularOtherNeurology
- Modalities
- Small moleculeEnzymeChemical drugsOther diagnostic agent
- Industry
- Academic Hospital/University/Research
02
Partnerships
Guangzhou Institute of Pharmaceutical Industry
Beyond the preview
Go deeper on Guangdong South China New Drug Creation Center.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangdong South China New Drug Creation Center.